We provide you with 20 years of free, institutional-grade data for AVRO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVRO. Explore the full financial landscape of AVRO stock.
| Reported Date | CIK | Ticker | Type |
|---|
AVROBIO, Inc(NASDAQ:AVRO) 
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functio...
Website: http://www.avrobio.com
Founded: 2015
Full Time Employees: 123
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about AVRO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.